Erlanger joins clinical trial aiming to reduce stroke in atrial fibrillation patients

Chattanooga, Tenn. – Erlanger Health System announces the Erlanger Heart and Lung Institute is participating in a clinical trial studying if blood thinners are more effective at preventing stroke in atrial fibrillation (AF) than the WATCHMAN device for left atrial appendage closure (LAAC). According to the Centers for Disease Control, Patients with AF are five … Continue reading Erlanger joins clinical trial aiming to reduce stroke in atrial fibrillation patients